Novo Nordisk follows Lilly into DTC obesity drug market
Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $499 per month for those paying out-of-pocket.
Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...
Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest clinical trial data for CagriSema, a treatment for adults with obesity or overweight and ...
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...
From STAT’s Elaine Chen: A federal judge this week ruled against a compounding trade group that wanted to continue making ...
Wall Street's major averages dipped for the week as investors wrestled with tariff twists from the Trump administration. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback